Crescent Biopharma (CBIO) Cash from Financing Activities (2013 - 2026)

Crescent Biopharma (CBIO) has 13 years of Cash from Financing Activities data on file, last reported at -$6.9 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$6.9 million, down 367.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $317.5 million (up 702.85% YoY), and the FY2025 annual result was $323.0 million, up 5983301.26% from the prior year.
• Cash from Financing Activities slipped to -$6.9 million in Q1 2026 per CBIO's latest filing, from $178.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $178.9 million in Q4 2025 and troughed at -$6.9 million in Q1 2026.
• A 4-year average of $32.2 million and a median of $12506.0 in 2023 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 29372700.0% in 2025 and fell as far as 30438.91% in 2025.
• A 4-year view of Cash from Financing Activities shows it stood at $999.0 in 2023, then surged by 4107507.61% to $41.0 million in 2024, then surged by 335.87% to $178.9 million in 2025, then sank by 103.88% to -$6.9 million in 2026.
• Business Quant data shows CBIO's Cash from Financing Activities at -$6.9 million in Q1 2026, $178.9 million in Q4 2025, and -$1.3 million in Q3 2025.